

Cansu Cimen Bozkus

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1357640/publications.pdf>

Version: 2024-02-01

16
papers

1,711
citations

1307594

7
h-index

1199594

12
g-index

16
all docs

16
docs citations

16
times ranked

5543
citing authors

#	ARTICLE	IF	CITATIONS
1	Immunology of COVID-19: Current State of the Science. <i>Immunity</i> , 2020, 52, 910-941.	14.3	1,387
2	Shared Immunogenic Poly-Epitope Frameshift Mutations in Microsatellite Unstable Tumors. <i>Cell</i> , 2020, 183, 1634-1649.e17.	28.9	103
3	Expression of Cationic Amino Acid Transporter 2 Is Required for Myeloid-Derived Suppressor Cell-Mediated Control of T Cell Immunity. <i>Journal of Immunology</i> , 2015, 195, 5237-5250.	0.8	74
4	Immune Checkpoint Blockade Enhances Shared Neoantigen-Induced T-cell Immunity Directed against Mutated Calreticulin in Myeloproliferative Neoplasms. <i>Cancer Discovery</i> , 2019, 9, 1192-1207.	9.4	65
5	Lynch Syndrome and MSI-H Cancers: From Mechanisms to "Off-The-Shelf" Cancer Vaccines. <i>Frontiers in Immunology</i> , 2021, 12, 757804.	4.8	31
6	PD-1 inhibition in advanced myeloproliferative neoplasms. <i>Blood Advances</i> , 2021, 5, 5086-5097.	5.2	16
7	A T-cell-based immunogenicity protocol for evaluating human antigen-specific responses. <i>STAR Protocols</i> , 2021, 2, 100758.	1.2	12
8	Calreticulin mutant myeloproliferative neoplasms induce MHC-I skewing, which can be overcome by an optimized peptide cancer vaccine. <i>Science Translational Medicine</i> , 2022, 14, .	12.4	10
9	Results of a Phase II Study of PD-1 Inhibition in Advanced Myeloproliferative Neoplasms. <i>Blood</i> , 2020, 136, 14-15.	1.4	6
10	SARS-CoV-2-specific T cells without antibodies. <i>Nature Reviews Immunology</i> , 2020, 20, 463-463.	22.7	3
11	Tumor organoid-originated biomarkers predict immune response to PD-1 blockade. <i>Cancer Cell</i> , 2021, 39, 1187-1189.	16.8	3
12	Long-lasting SARS-CoV-2-specific T cell memories. <i>Nature Reviews Immunology</i> , 2020, 20, 593-593.	22.7	1
13	772...MHC-I skewing in mutant calreticulin-positive myeloproliferative neoplasms is countered by heteroclitic peptide cancer vaccination. , 2021, 9, A807-A807.		0
14	334...Phase I study of safety and activity of personalized neoantigen-based vaccines in combination with tumor treating fields for newly diagnosed glioblastoma patients. , 2021, 9, A360-A360.		0
15	444...MHC-I skewing in mutant calreticulin-positive myeloproliferative neoplasms is countered by heteroclitic peptide cancer vaccination. , 2020, , .		0
16	Abstract 1379: Discovery of tumor-associated, immunogenic peptides presented in a patient-derived, mutant calreticulin-driven myeloproliferative neoplasm cell line. <i>Cancer Research</i> , 2022, 82, 1379-1379.	0.9	0